Evidence map›Paper›PMID 34518543›Full record

ArticleNPJ vaccines2021

Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome.

Andrea A Berry, Joshua M Obiero, Mark A Travassos, Amed Ouattara, Drissa Coulibaly, Matthew Adams, Rafael Ramiro de Assis, Aarti Jain, Omid Taghavian, Andrew Sy and 13 more

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 1 country.

Andrea A Berry *Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. aberry@som.umaryland.edu.ORCID http://orcid.org/0000-0003-3140-3868
Joshua M Obiero *Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-9741-512X
Mark A TravassosCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Amed OuattaraCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Drissa CoulibalyMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Matthew AdamsCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Rafael Ramiro de AssisDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.ORCID http://orcid.org/0000-0003-0165-8106
Aarti JainDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Omid TaghavianDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Andrew SyDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Rie NakajimaDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Algis JasinskasDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Matthew B LaurensCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-3874-581X
Shannon Takala-HarrisonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Bourema KouribaMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.ORCID http://orcid.org/0000-0002-3419-5972
Abdoulaye K KoneMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Ogobara K DoumboMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
B Kim Lee SimSanaria Inc., Rockville, MD, USA.
Stephen L HoffmanSanaria Inc., Rockville, MD, USA.ORCID http://orcid.org/0000-0002-0700-9505
Christopher V PloweCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Mahamadou A TheraMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Philip L FelgnerDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Kirsten E LykeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
University of California, Irvine · USUniversity of Maryland, Baltimore · USSanaria · US

Funding

QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WHITE, OWEN R · 2014 to 2023
$36.5M
Clinical trial of trimethoprim-sulfamethoxazole or chloroquine in adults on ARTU01AI089342 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LAUFER, MIRIAM K. · 2011 to 2017
$13.7M
Plasmodium Falciparum Whole Sporozoite Malaria VaccineR44AI055229 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2005 to 2015
$10.0M
TransmissionU19AI089686 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ZIMMERMAN, PETER A. · 2010 to 2016
$9.9M
Universal Attenuated Sporozoite Vaccine and Challenge SystemR44AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2006 to 2018
$9.9M
Safety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2005 to 2009
$4.7M
Genome-wide sieve analysis and immunological validation to identify targets of protective efficacy in field trials of a whole-organism malaria vaccineR01AI141900 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CARNEIRO DA SILVA, JOANA · 2019 to 2023
$3.9M
MALARIA RESEARCH TRAINING IN MALID43TW001589 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2000 to 2015
$2.8M
A Systems Biology Approach to Malaria ImmunityU01AI110852 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI WILLIAMSON, KIM C · 2016 to 2019
$2.8M
Variant surface antigens in cerebral malaria pathogenesisR01HL130750 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI FISHER, STEVEN A., HARRISON, SHANNON TAKALA · 2015 to 2018
$2.1M
Predicting naturally acquired humoral immunity against malariaR01AI095916 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FELGNER, PHILIP LOUIS · 2012 to 2016
$2.1M
FIC NIH HHS D43 TW001589NCATS NIH HHS UL1 TR003098NHLBI NIH HHS K01 HL140285NHLBI NIH HHS R01 HL130750NIAID NIH HHS HHSN272200800057CNIAID NIH HHS HHSN272201500002CNIAID NIH HHS K23 AI125720NIAID NIH HHS N01 AI025461NIAID NIH HHS R01 AI067954NIAID NIH HHS R01 AI095916NIAID NIH HHS R01 AI141900NIAID NIH HHS R44 AI055229NIAID NIH HHS R44 AI058375NIAID NIH HHS U01 AI089342NIAID NIH HHS U01 AI110852NIAID NIH HHS U19 AI065683NIAID NIH HHS U19 AI089686NIAID NIH HHS U19 AI110820U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) K01HL140285-01A1U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K23AI125720U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI095916U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI089686
6 · The paper itself

Abstract

Knowledge of the Plasmodium falciparum antigens that comprise the human liver stage immunoproteome is important for pre-erythrocytic vaccine development, but, compared with the erythrocytic stage immunoproteome, more challenging to classify. Previous studies of P. falciparum antibody responses report IgG and rarely IgA responses. We assessed IgG and IgA antibody responses in adult sera collected during two controlled human malaria infection (CHMI) studies in malaria-naïve volunteers and in 1- to 6-year-old malaria-exposed Malian children on a 251 P. falciparum antigen protein microarray. IgG profiles in the two CHMI groups were equivalent and differed from Malian children. IgA profiles were robust in the CHMI groups and a subset of Malian children. We describe immunoproteome differences in naïve vs. exposed individuals and report pre-erythrocytic proteins recognized by the immune system. IgA responses detected in this study expand the list of pre-erythrocytic antigens for further characterization as potential vaccine candidates.

Identifiers

PMID34518543
PMCPMC8438027
OpenAlexW3199536645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.